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Abstract
Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), is a highly aggressive monogenic cancer driven by SMARCA4
mutations. Here, we report responses to anti-PD1 immunotherapy in four patients and characterize the immune landscape of
SCCOHT tumors using quantitative immunofluorescence and gene expression profiling. Unexpectedly for a low mutation bur-
den cancer, the majority of the tumors (eight of 11 cases) demonstrated PD-L1 expression with strong associated T-cell infiltra-
tion (R2 ¼ 0.60–0.95). PD-L1 expression was detected in both tumor and stromal cells, with macrophages being the most abun-
dant PD-L1-positive cells in some tumors (three of 11 cases). Transcriptional profiling revealed increased expression of genes
related to Th1 and cytotoxic cell function in PD-L1-high tumors, suggesting that PD-L1 acts as a pathway of adaptive immune
resistance in SCCOHT. These findings suggest that although SCCOHT are low–mutational burden tumors, their immunogenic
microenvironment resembles the landscape of tumors that respond well to treatment with PD-1/PD-L1 blockade.
Small cell carcinoma of the ovary, hypercalcemic type
(SCCOHT), is a rare and very aggressive malignancy that occurs
mostly in young women (1). We and others previously described
SCCOHT as a SMARCA4-mutated monogenic disease (2–6).
Despite recent advances in understanding SCCOHT biology,
there are few effective treatments, and survival remains poor.
Immunotherapy utilizing antibodies against the immune
checkpoint inhibitor programmed death 1 (PD-1) is active in
many cancers (7–12). High tumor mutational load, presence of
tumor-infiltrating lymphocytes (TILs), and PD-L1 expression in
the microenvironment appear to enrich for response to PD-1/
PD-L1 blockade (13–15). Studies in gynecologic malignancies, in-
cluding microsatellite instability (MSI), demonstrate that an in-
crease in mutational burden is associated with increased TILs
and tumor PD-L1 expression (16–18).
SCCOHT is a monogenic disease and as such is not hyper-
mutated (2–6), which may otherwise dampen enthusiasm for
immunotherapy. The activity of PD-1/PD-L1 blockade in these
tumors has not been reported, yet several patients with
SCCOHT have received anti-PD1 immunotherapy with sug-
gested benefit. We collected case histories from four patients di-
agnosed at age 18 to 29 years (details in the Supplementary
Materials, available online). Each patient was found to have a
large ovarian tumor and underwent surgery that resulted in
complete tumor resection; all recurred after a disease-free inter-
val of one to three years. Each patient received additional ther-
apy and then began treatment with anti-PD1 immunotherapy.
One patient has a sustained partial response for six months,
and the three other patients have remained disease-free for 1.5
years or more. This study was determined to be institutional re-
view board–exempt; however, each patient did provide written
permission to be included in this report. All statistical tests
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Though we were unable to obtain biospecimens from these
four patients, these anecdotal findings prompted us to study
the tumor microenvironment to examine the rationale for im-
munotherapeutic approaches in SCCOHT. Using immunohisto-
chemistry (IHC) and immunofluorescence (IF) analyses, we
assessed tumor expression of PD-L1, CD3 (T cells), and CD68
(macrophages) in 11 SCCOHT cases. All but one patient demon-
strated either a deleterious mutation in SMARCA4 or loss of
SMARCA4 expression by IHC (Supplementary Table 1, available
online) without any additional genetic alterations, highlighting
the low tumor mutational burden of these tumors.
Unexpectedly for a cancer with few somatic mutations, PD-
L1 expression (range ¼ 9–287 cells per high-power field [HPF])
and prominent T-cell infiltration (range ¼ 3–296 cells per HPF)
were detected in most tumors (10 of 11 cases) (Figure 1, A–C).
The majority of the tumors (10 of 11 cases) also demonstrated
infiltration by CD68þ macrophages (range ¼ 10–241 cells per
HPF) (Figure 1D). Similar to reports in other solid tumors, PD-L1
expression was detected in both tumor cells and stromal cells,
and in three cases tumor-associated macrophages were the
most abundant PD-L1-positive cells (Figure 1, A and E;
Supplementary Figure 1, available online).
There was a strong association between T-cell infiltration
and PD-L1 expression across all patients (R2 ¼ 0.46, P ¼ .02;
Pearson correlation) (Figure 1F), and on a per-field basis in each
patient, apart from those with the lowest PD-L1 positivity
(Supplementary Figure 2A, available online). PD-L1 expression
was statistically significantly associated with T-cell infiltration
in eight of 11 cases (R2 ¼ 0.60–0.95, P < .05). There was no associ-
ation between macrophages and T-cell infiltration, and there
was a poor association between PD-L1 expression and tumor
macrophage infiltration (Supplementary Figure 2, B and C avail-
able online). The latter finding suggests that macrophage re-
cruitment and upregulation of PD-L1 expression are mediated
by different mechanisms.
The association between PD-L1 expression and T-cell infil-
tration suggests that PD-L1 expression is likely not intrinsic, but
rather a mechanism of adaptive immune resistance to TILs, and
is likely upregulated in response to production of IFNc in the tu-
mor microenvironment (13,19). The differential expression of
PD-L1 by the macrophages and cancer cells between the
patients could imply intrinsic biologic differences between the
cells or differential responses to T-cell-produced IFNc (21).
To characterize the tumor inflammatory responses and their
association with PD-L1 expression in more detail, we performed
gene expression profiling using NanoString’s nCounter
PanCancer Immunoprofiling panel (Figure 2). Most differentially
expressed genes (34 of 36, P < .05) were elevated in the high-PD-
L1 group and were T-cell specific or cytotoxicity related
(Supplementary Table 2, available online). The differentially
expressed gene set closely corresponds to the recently reported
transcriptional signature associated with response to
pembrolizumab (Supplementary Table 2, available online) (22).
The expression of PDCD1 (encoding for PD-1), previously
associated with response to PD-1 blockade, was higher in the
high-PD-L1 group (fold change ¼ 2.3, 95% confidence interval
Figure 1. Small cell carcinoma of the ovary, hypercalcemic type (SCCOHT), exhibit immune-active tumor microenvironment. A) Immunohistochemistry triple-staining
with the PD-L1, CD3, and CD68 antibodies of three representative SCCOHT cases. Enlarged outset demonstrates merged triple-stain, showing overlap of PD-L1- and
CD68-positive cells but not CD3-positive cells. Scale bars ¼ 50 mm. B) PD-L1-positive, C) CD3-positive, and D) CD68-positive cell counts per high-power field (HPF). The y-
axis indicates number of marker-positive cells, and the x-axis indicates SCCOHT cases. Error bars represent one SD per 10 HPFs. E) Percentage of CD68þ cells out of all
PD-L1-expressing cells. The y-axis indicates percentage of PD-L1-expressing macrophages, and the x-axis indicates SCCOHT cases. Error bars represent one SD per 10
HPFs. F) Correlation of PD-L1 and CD3 expression in all SCCOHT cases. Each black dot represents an individual HPF. Each purple square represents the mean of 10 HPFs
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[CI] ¼ 1.4 to 3.8, P ¼ .03) (Figure 2A) (13). CD274 (encoding for PD-
L1) also had higher (but not statistically significant) expression
in the high-PD-L1 group, possibly due to heterogeneity of the
PD-L1-positive cells or post-transcriptional regulation of PD-L1
expression. Gene expression–based cell type deconvolution
demonstrated that all immune cell types were more common in
the high-PD-L1 group, further confirming correlation between
PD-L1 positivity and enhanced immune response (Figure 2B).
Among the highest cell type scores, in addition to B cells, were
cell types known to be involved in antitumor activity such as T
cells, Th1, CD8, and cytotoxic cells (Figure 2, B–D;
Supplementary Figure 2C, available online). Two genes encod-
ing for CD3, CD3E (fold change ¼ 3.1, 95% CI ¼ 1.3 to 7.2, P ¼ .05)
and CD3D (fold change ¼ 3.5, 95% CI ¼ 1.4 to 8.6, P ¼ .04), were
elevated in the high-PD-L1 group, supporting our observations
from the IHC experiments that TILs and PD-L1-positive
cells coexist in SCCOHTs (Figure 2D). Cytolytic and
antigen-presenting genes were also noted to be elevated in the
high-PD-L1 group (Figure 2, E and F). Among cytotoxic genes, a
statistically significant increase in perforin 1 (PRF1; fold change
¼ 3.2, 95% CI ¼ 2.4 to 4.5, P < .001), granzyme B (GZMB; fold
change ¼ 4.3, 95% CI ¼ 1.7 to 10.6, P ¼ .03), granulysin (GNLY;
fold change ¼ 4.6, 95% CI ¼ 1.8 to 11.7, P ¼ .03), and granzyme H
(GZMH; fold change ¼ 2.5, 95% CI ¼ 1.3 to 4.8, P ¼ .04) (Figure 2E)
highlighted the association between PD-L1 expression and cyto-
toxic cell activity. KEGG pathway analysis revealed increased
activity in the T-cell receptor signaling pathway, supporting our
observation that TILs are engaged in active immune response in
SCCOHTs (Supplementary Figure 3, available online).
Interestingly, two of the PD-L1-high cases exhibited
macrophage-predominant PD-L1 expression (102 and 117), and
the other two expressed PD-L1 predominantly in tumor cells
(cases 101 and 121). Similarly, in the PD-L1-low group, PD-L1 ex-
pression was primarily seen in macrophages in cases 115 and
116 and in tumor cells in cases 114 and 118. There did not
appear to be meaningful differences in T-cell-related gene
Figure 2. PD-L1 expression is associated with T cell-related gene expression in small cell carcinoma of the ovary, hypercalcemic type (SCCOHT). A) Normalized gene ex-
pression of PDCD1 (encoding for PD1) and CD274 (encoding for PD-L1) in the high-PD-L1 vs low-PD-L1 cases. Box plots superimposed on violin plots in figures (A), (D),
and (E) represent differential gene expression. Boxplot center lines represent tumor medians, box limits are the interquartile range from 25% and 75%, and whiskers
represent the extent of tumors out to 1.5 times the interquartile range. The gray shading of the violin plots represents the estimated distribution of the expression val-
ues. Dots represent individual cases. B) Relative abundance of specific cell types in high-PD-L1 vs low-PD-L1 cases. Cell type scores are mean centered based on decon-
volution of cell type–specific gene sets. C) T-cell scores in the high-PD-L1 vs low-PD-L1 group. D and E) Volcano plots of differentially expressed genes showing the T-
cell-related genes (blue dots) and cytotoxicity genes (red dots), respectively. Expression of representative genes are shown to the right of each plot. Statistically signifi-
cant genes are shown above the dashed line on the volcano plots (P ¼ .05), and individual genes are shown adjacent. F) Unsupervised clustering of cytotoxicity-related
and MHC class I genes for high-PD-L1 and low-PD-L1 cases. PD-L1 group is indicated by the color bar at the top of the figure (green: low-PD-L1; orange: high-PD-L1). All
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expression between the subgroups in either the PD-L1-high
group or the PD-L1-low group (Supplementary Figure 4, avail-
able online).
These data suggest that SCCOHTs are immunogenic tumors
and exhibit biologically significant levels of T-cell infiltration
and PD-L1 expression. These findings are somewhat unex-
pected, given the low mutational burden in these tumors.
SMARCA4 is a member of the chromatin remodeling SWI/SNF
complex that is involved in many biological processes including
transcriptional regulation (23). The transcriptional program reg-
ulated by SMARCA4 may influence tumor immunogenicity,
leading to TIL infiltration and PD-L1 upregulation. Given that
SCCOHT is a monogenic disease, this immunogenicity may de-
rive from the loss of SMARCA4 function. Given that SCCOHT is a
rare disease, the major limitation of our study is the small num-
ber of cases. Another limitation is that tissue from the patients
who received anti-PD1 immunotherapy was not available.
These data describe the immune landscape and tumor mi-
croenvironment of SCCOHT tumors, which resembles other im-
munogenic tumors that respond well to anti-PD-1
immunotherapies, generating a strong rationale for evaluation
of these agents in SCCOHT patients. The findings underscore
inconsistencies between mutational burden and immunogenic-
ity, emphasizing the need for additional biomarkers to assess
tumor recognition by the immune system.
Funding
We are grateful for funding provided by the Katie Oppo
Research Fund, Arnold Chavkin and Laura Chang, US
Department of Defense Consortium Award W81XWH-11-2-
0230, NIH P30 CA008748, NIH P30 CA016087, and support
from the Small Cell Ovarian Cancer Foundation. DZ received
funding from the Ovarian Cancer Research Foundation,
MSKCC Cycle for Survival, and the US Department of
Defense Ovarian Cancer Academy (W81XWH-16-1-0298).
Notes
We appreciate the support of all the patients who shared bio-
logic specimens and clinical information for this report. We are
thankful to Yanyun Li for help with pathology and
quantification.
The funders had no role in the design of the study; the col-
lection, analysis, or interpretation of the data; the writing of the
manuscript; or the decision to submit the manuscript for
publication.
The authors declare no competing financial interests.
References
1. Young RH, Oliva E, Scully RE. Small cell carcinoma of the ovary, hypercalce-
mic type. A clinicopathological analysis of 150 cases. Am J Surg Pathol. 1994;
18(11):1102–1116.
2. Jelinic P, Mueller JJ, Olvera N, et al. Recurrent SMARCA4 mutations in small
cell carcinoma of the ovary. Nat Genet. 2014;46(5):424–426.
3. Ramos P, Karnezis AN, Craig DW, et al. Small cell carcinoma of the ovary, hy-
percalcemic type, displays frequent inactivating germline and somatic muta-
tions in SMARCA4. Nat Genet. 2014;46(5):427–429.
4. Witkowski L, Carrot-Zhang J, Albrecht S, et al. Germline and somatic
SMARCA4 mutations characterize small cell carcinoma of the ovary, hyper-
calcemic type. Nat Genet. 2014;46(5):438–443.
5. Jelinic P, Schlappe BA, Conlon N, et al. Concomitant loss of SMARCA2 and
SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic
type. Mod Pathol. 2016;29(1):60–66.
6. Karnezis AN, Wang Y, Ramos P, et al. Dual loss of the SWI/SNF complex
ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific
for small cell carcinoma of the ovary, hypercalcaemic type. J Pathol. 2016;
238(3):389–400.
7. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: A common
denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450–461.
8. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy.
Nat Rev Cancer. 2012;12(4):252–264.
9. Hamanishi J, Mandai M, Iwasaki M, et al. Programmed cell death 1 ligand 1
and tumor-infiltrating CD8þ T lymphocytes are prognostic factors of human
ovarian cancer. Proc Natl Acad Sci U S A. 2007;104(9):3360–3365.
10. Nghiem PT, Bhatia S, Lipson EJ, et al. PD-1 blockade with pembrolizumab in
advanced merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542–2552.
11. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in ad-
vanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373(2):
123–135.
12. Boussiotis VA. Molecular and biochemical aspects of the PD-1 checkpoint
pathway. N Engl J Med. 2016;375(18):1767–1778.
13. Tumeh PC, Harview CL, Yearley JH, et al. PD-1 blockade induces responses by
inhibiting adaptive immune resistance. Nature. 2014;515(7528):568–571.
14. Larkin J, Chiarion-Sileni V, Gonzalez R, et al. Combined nivolumab and ipili-
mumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373(13):
1270–1271.
15. Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mutational
landscape determines sensitivity to PD-1 blockade in non-small cell lung
cancer. Science. 2015;348(6230):124–128.
16. Pakish JB, Zhang Q, Chen Z, et al. Immune microenvironment in microsatel-
lite instable endometrial cancers: Hereditary or sporadic origin matters. Clin
Cancer Res. 2017;23(15):4473–4481.
17. Strickland KC, Howitt BE, Shukla SA, et al. Association and prognostic signifi-
cance of BRCA1/2-mutation status with neoantigen load, number of tumor-
infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous
ovarian cancer. Oncotarget. 2016;7(12):13587–13598.
18. Howitt BE, Shukla SA, Sholl LM, et al. Association of polymerase e-mutated
and microsatellite-instable endometrial cancers with neoantigen load, num-
ber of tumor-infiltrating lymphocytes, and expression of PD-1 and PD-L1.
JAMA Oncol. 2015;1(9):1319–1323.
19. Spranger S, Spaapen RM, Y. Z, et al. Up-regulation of PD-L1, IDO, and tregs in
the melanoma tumor microenvironment is driven by CD8þ T cells. Sci Transl
Med. 2013;5(200):5(200):200ra116.
20. Powles T, Eder JP, Fine GD, et al. MPDL3280A (anti-PD-L1) treatment leads to
clinical activity in metastatic bladder cancer. Nature. 2014;515(7528):558–562.
21. Garcia-Diaz A, Shin DS, Moreno BH, et al. Interferon receptor signaling path-
ways regulating PD-L1 and PD-L2 expression. Cell Rep. 2017;19(6):1189–1201.
22. Ayers M, Lunceford J, Nebozhyn M, et al. IFN-gamma-related mRNA profile
predicts clinical response to PD-1 blockade. J Clin Invest. 2017;127(8):
2930–2940.
























niversity user on 02 M
arch 2021
